Streetbeat News

Revenues

SXC

SunCoke Energy (SXC) provides its 2024 financial outlook, expecting net income between $67M-$84M, adjusted EBITDA of $240M-$255M, and domestic coke production of approximately 4.1 million tons. Capital expenditures are projected at $95M, with operating cash flow estimated between $75M-$80M.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:41 am

RGEN

Repligen has reaffirmed its 2024 sales guidance, projecting revenues to be in the range of $620M-$650M, aligning closely with the consensus estimate of $637.79M.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:34 am

NCLH

Norwegian Cruise Lines (NCLH) updated its FY24 financial outlook, reporting record bookings in Q1, leading to a record booked position for the next twelve months. The company raised its 2024 full year Net Yield guidance on a Constant Currency basis by 100 basis points to approximately 6.4% from 5.4%. Adjusted EBITDA guidance for 2024 increased by $50 million to about $2.25 billion, and Adjusted Net Income guidance rose by $45 million to $680 million. Consequently, Adjusted EPS guidance for 2024 was revised upwards to $1.32 from the previous $1.23, still below the $1.73 estimate.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:33 am

ROCK

Gibraltar Industries has reaffirmed its 2024 financial outlook, projecting 4-9% revenue growth and 12-20% EPS growth. This positive forecast reflects the company's confidence in its strategic initiatives and market position.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:31 am

DAY

Dayforce projects its Q2 2024 revenue to be in the range of $414M-$419M, which is around the analyst estimate of $417.508M.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:29 am

DAY

Dayforce projects its FY24 revenue to be between $1.730 billion and $1.740 billion, slightly above the estimated $1.726 billion.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:29 am

VRSK

Verisk Analytics has reaffirmed its fiscal year 2024 revenue forecast to be in the range of $2.84 billion to $2.90 billion, closely aligning with the analyst estimate of $2.88 billion. The company also provided guidance for its diluted adjusted EPS, projecting it to be between $6.30 and $6.60, which brackets the analyst estimate of $6.51.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:21 am

TGTX

TG Therapeutics shares surged after the company reported a Q1 revenue beat and raised its 2024 Briumvi US net product revenue outlook.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:17 am

BCDA

BioCardia announced results from its open label roll-in cohort study for patients with chronic myocardial ischemia and refractory angina, showing an average increase in exercise tolerance of 107 seconds and an average reduction in angina episodes of 82% at the six-month follow-up.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:15 am

CMRX

Chimerix announced expectations for interim overall survival data for Dordaviprone in 2025 and final data in 2026. Dordaviprone is a novel oral molecule targeting DRD2 and ClpP for potential therapeutic applications.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:13 am